Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study ( CladStop )
European Journal of Neurology · 2024-06 · 31 (6)
DOI: 10.1111/ene.16250 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 28.03.2024. Verfasst von Irene Schiavetti und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Genoa, Genova, Italy. Hauptthemen laut MEDLINE: Cladribine, Immunosuppressive Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment needed in years 3 and 4. However, comprehensive evidence regarding patient outcomes beyond the initial 24 months of cladribine treatment is limited.
Methods
This retrospective, multicenter study enrolled 204 patients with multiple sclerosis who had completed the 2‐year course of cladribine treatment. The primary outcomes were therapeutic choices and clinical disease activity assessed by annualized relapse rate after the 2‐year treatment course.
Results
A total of 204 patients were enrolled; most patients (75.4%) did not initiate new treatments in the 12 months postcladribine. The study found a significant reduction in annualized relapse rate at the 12‐month follow‐up after cladribine completion compared to the year prior to starting therapy (0.07 ± 0.25 vs. 0.82 ± 0.80, p < 0.001). Furthermore, patients with relapses during cladribine treatment were more likely to start new therapies, whereas older patients were less likely. The safety profile of cladribine was favorable, with lymphopenia being the primary registered adverse event.
Conclusions
This study provides insights into therapeutic choices and disease activity following cladribine treatment. It highlights cladribine's effectiveness in reducing relapse rates and disability progression, reaffirming its favorable safety profile. Real‐world data, aligned with previous reports, draw attention to ocrelizumab and natalizumab as common choices after cladribine. However, larger, prospective studies for validation and a more comprehensive understanding of cladribine's long‐term impact are necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University of Genoa, Genova, Italy.
- Centro Sclerosi Multipla Ospedale Binaghi Cagliari, Azienda Sanitaria Locale (ASL) Cagliari, Cagliari, Italy.
- Dipartimento Scienze Mediche e Sanità Pubblica, Università di Cagliari, Cagliari, Italy.
- Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Pozzilli, Italy.
- Department of Systems Medicine, Tor Vergata University, Rome, Italy.
- Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
ORCID-Profile: Irene Schiavetti, Jessica Frau, Diego Centonze, Doriana Landi, Elisabetta Signoriello, Chiara Zecca, Claudio Gobbi, Diana Ferraro, Simona Bonavita, Massimiliano Di Filippo
Zitieren
APA
Schiavetti, I., Signori, A., Albanese, A., Frau, J., Cocco, E., Lorefice, L., di Lemme, S., Fantozzi, R., Centonze, D., Landi, D., Marfia, G., Signoriello, E., Lus, G., Zecca, C., Gobbi, C., Iodice, R., Malimpensa, L., Cordioli, C., Ferraro, D., …, & CladStop study group (2024). Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study ( CladStop ). European Journal of Neurology, 31(6). https://doi.org/10.1111/ene.16250
Vancouver
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, et al. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study ( CladStop ). European Journal of Neurology. 2024;31(6). doi:10.1111/ene.16250
BibTeX
@article{Schiavetti2024,
author = {Schiavetti, Irene and Signori, Alessio and Albanese, Angela and Frau, Jessica and Cocco, Eleonora and Lorefice, Lorena and di Lemme, Sonia and Fantozzi, Roberta and Centonze, Diego and Landi, Doriana and Marfia, Girolama and Signoriello, Elisabetta and Lus, Giacomo and Zecca, Chiara and Gobbi, Claudio and Iodice, Rosa and Malimpensa, Leonardo and Cordioli, Cinzia and Ferraro, Diana and Ruscica, Francesca and Pasquali, Livia and Repice, Anna and Immovilli, Paolo and Ferrò, Maria Teresa and Bonavita, Simona and Di Filippo, Massimiliano and Abbadessa, Gianmarco and Govone, Flora and Sormani, Maria Pia and CladStop study group, CladStop study group},
title = {Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study ( CladStop )},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {6},
doi = {10.1111/ene.16250}
}
EUVIMED